SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases, today
announced that Matthew R. Patterson,
President and Chief Executive Officer, will present a corporate
overview at the Alliance for Regenerative Medicine's
5th Annual Cell & Gene Therapy Investor Day in
Boston, MA. The presentation
is scheduled for Thursday, April 27,
2017, at 9:55 am ET.
To access a live webcast of the presentation, please visit the
Events & Presentations page within the Investors & News
section of the Audentes website. Replays of live webcasts
will be available on the Audentes website for approximately 30 days
following the conference.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology
company focused on developing and commercializing gene therapy
products for patients living with serious, life-threatening rare
diseases. We have four product candidates in development,
AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM),
AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the
treatment of Pompe disease, and AT307 for the treatment of the
CASQ2 subtype of Catecholaminergic Polymorphic Ventricular
Tachycardia (CASQ2-CPVT). We are a focused, experienced and
passionate team committed to forging strong, global relationships
with the patient, research and medical communities.
For more information regarding Audentes, please
visit www.audentestx.com.
Audentes Contacts:
Investor Contact:
Thomas Soloway, CFO
415.818.1040
ir@audentestx.com
Media Contact:
Jeffrey Gruis
415.818.1015
media@audentestx.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-the-arm-5th-annual-cell--gene-therapy-investor-day-300440070.html
SOURCE Audentes Therapeutics, Inc.